These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 19001145)

  • 21. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
    Jaber SH; Cowen EW; Haworth LR; Booher SL; Berman DM; Rosenberg SA; Hwang ST
    Arch Dermatol; 2006 Feb; 142(2):166-72. PubMed ID: 16490844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
    Korman A; Yellin M; Keler T
    Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of CD28 expression on CD8+ T cells by CTLA-4.
    Berg M; Zavazava N
    J Leukoc Biol; 2008 Apr; 83(4):853-63. PubMed ID: 18162511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Peggs KS; Quezada SA; Korman AJ; Allison JP
    Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.
    Hoff H; Knieke K; Cabail Z; Hirseland H; Vratsanos G; Burmester GR; Jorch G; Nadler SG; Bröker B; Hebel K; Brunner-Weinzierl MC
    J Immunol; 2009 May; 182(9):5342-51. PubMed ID: 19380781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
    Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
    Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances using anti-CTLA-4 for the treatment of melanoma.
    Sarnaik AA; Weber JS
    Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
    Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
    Chin LT; Chu C; Chen HM; Wang DW; Liao SK
    Chang Gung Med J; 2008; 31(1):1-15. PubMed ID: 18419049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
    Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
    Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of co-inhibitory signals driven by CTLA-4 in immune system].
    Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA
    Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies.
    Kroczek R; Hamelmann E
    J Allergy Clin Immunol; 2005 Oct; 116(4):906-9. PubMed ID: 16210068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-PD-1 antibody: basics and clinical application].
    Tanaka Y; Okamura H
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections.
    Pentcheva-Hoang T; Corse E; Allison JP
    Immunol Rev; 2009 May; 229(1):67-87. PubMed ID: 19426215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
    Page DB; Yuan J; Wolchok JD
    Immunotherapy; 2010 May; 2(3):367-79. PubMed ID: 20635901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.